NASA has issued another grant to Collins Aerospace to design the future of spacewalks and moonwalks. Image via NASA

Charlotte, North Carolina-based Collins Aerospace has been selected by NASA to develop a spacewalking system for the astronauts aboard the International Space Station.

The award, which is the second under NASA’s Exploration EVA Services contract, has a base value of $97.2 million, per a Dec. 8 news release from NASA. The company has until January 2024 "to complete a critical design review and demonstrate use of the suit on Earth in a simulated space environment," according to NASA, which will then decide the option to extend the contract for testing to be conducted by April 2026.

NASA’s Johnson Space Center in Houston manages the spacesuit contract. Collins Aerospace has had a presence in Houston for 40 years, and recently cut the ribbon on a $30 million facility near the JSC.

“We look forward to obtaining another much-needed service under our contract,” says Lara Kearney, manager of the Extravehicular Activity and Human Surface Mobility Program at JSC, in the release. “By working with industry, NASA is able to continue its over 22-year legacy of maintaining a presence in low-Earth orbit.”

The current system was designed decades ago and has been used during previous space shuttle and space station missions. Collins Aerospace will work with Houston-based Axiom Space on this project, which was initially announced this summer.

"Both vendors will continue to compete for future task orders which include recurring services for station spacewalks and moonwalks beyond Artemis III," the news release reads.

Axiom Space will outfit our astronauts. Photo courtesy of NASA

Houston tech company lands exclusive spacesuit deal for NASA's mission to moon

suit up

When astronauts make a historic return to the surface of the moon, presumably 2025 or 2026, they’ll don Houston-crafted, life-protecting suits.

Houston-based Axiom Space has landed the rights to create spacesuits and supporting systems for NASA’s Artemis III mission, which will see humans back on our satellite for the first time since the legendary Apollo missions more than 50 years ago.

This award is the first for a competitive spacesuits contract, NASA notes in a press release. NASA tapped Axiom Space for a task order boasting a base value of $228.5 million. As previously reported, Axiom Space was one of two companies NASA pegged for spacesuit and supporting system development.

These new suits are pivotal, as plans for NASA’s Artemis lunar program call for not just lunar orbit, but trips to the lunar south pole and even a crewed outpost on the moon.

Axiom Space will be responsible for the design, development, qualification, certification, and production of its spacesuits and support equipment. Spacesuits will be tested for moonwalks and spacewalks.

This spacesuit contract, which will advance spacewalking capabilities in low-Earth orbit and on the Moon, is managed by the Extravehicular Activity and Human Surface Mobility Program (EHP) at Johnson Space Center.

“NASA is proud to partner with commercial industry on this historic mission that will kickstart the United States building a lasting presence on the surface of the Moon,” said Lara Kearney, manager of NASA’s Extravehicular Activity and Human Surface Mobility program. “What we learn on Artemis III and future missions on and around the Moon will pave the way for missions to Mars. Spacesuits enable us to literally take that next step.”

The first lunar mission since 1972, Artemis will be historic in myriad ways, none of least for seeing the first woman and the first person of color on the moon, as well as a testing ground for eventual Mars missions.

Artemis I is set to launch on September 19, barring any delays.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”